Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study.
Pharmacoecon Open
; 3(3): 333-342, 2019 Sep.
Article
in En
| MEDLINE
| ID: mdl-30684255
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Health_economic_evaluation
/
Observational_studies
Language:
En
Journal:
Pharmacoecon Open
Year:
2019
Type:
Article
Affiliation country:
Spain